Claim check · Study interpretation, Effectiveness
Cell and animal results versus human results
Claim (representative wording, not a quotation): It worked in cells and mice, so it works in people.
Plain-English answer
A good result in cells or animals shows a compound is worth testing in people. It does not show the compound works in people. For elamipretide (SS-31), aged mice showed better muscle energy use and endurance, but in a randomized phase 3 trial in adults with primary mitochondrial myopathy it did not beat placebo on walking distance or fatigue. The mouse work was in aging, not in this disease, so this illustrates the gap and does not show the mouse result was wrong.
Verdict: Overstated. Part of the claim is supported, but the claim says more than the sources show: a wider population, a stronger outcome, a human result from animal work, or a certainty the design cannot give.
Scope
- Population or organism
- One compound in two settings: aged mice (27 months old), and adults with genetically confirmed primary mitochondrial myopathy (218 randomized)
- Study design
- One mouse experiment compared with one randomized, double-blind, placebo-controlled phase 3 trial
- Boundary
- An illustration for one compound. It is not a measure of how often animal results carry over to people, not evidence that the mouse finding was wrong, and not about the approved Barth syndrome use. The mouse study was in aging muscle, a different cause from genetic mitochondrial myopathy. WPF did not find an original animal study in a primary mitochondrial myopathy model.
Strongest evidence
Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice (Aging Cell, 2013; PMID 23692570; DOI 10.1111/acel.12102) (Peer-reviewed paper)
Population or organism: Young (5 months) and old (27 months) mice
Design: Animal experiment: injection of SS-31 or saline, muscle energetics measured in vivo
Where in the source: Abstract: a single SS-31 treatment restored in vivo muscle mitochondrial energetics in aged mice after one hour, with no observable effect on young muscle; aged muscle was more fatigue resistant in situ; eight days of treatment increased whole-animal endurance capacity.
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial (Neurology, 2023; PMID 37268435; DOI 10.1212/WNL.0000000000207402) (Peer-reviewed paper)
Population or organism: 218 adults with genetically confirmed primary mitochondrial myopathy, randomized 109 to 109
Design: Phase 3, randomized, double-blind, placebo-controlled, 24 weeks; primary endpoints were change in 6-minute walk distance and total fatigue score
Where in the source: Abstract, Results: the study did not meet its primary endpoints; the difference in least-squares mean change in 6-minute walk distance was -3.2 meters (95% CI -18.7 to 12.3; p = 0.69), with the comparison ordered elamipretide versus placebo.
ClinicalTrials.gov NCT03323749 (MMPOWER-3, terminated) (Registry record)
Population or organism: 218 participants (actual enrollment)
Design: Registered phase 3 randomized trial
Where in the source: Record header: status Terminated, reason given as "Part1,double blind portion of the trial did not meet the primary end points". Results tab, primary outcome 1 (6-minute walk, change from baseline, observed means by visit): at week 24, +15.330 m (SD 61.486, n = 100) with elamipretide and +17.386 m (SD 51.696, n = 102) with placebo. Primary outcome 2 (total fatigue score, 4 to 16, lower is better): at week 24, -1.18 (SD 2.132, n = 98) with elamipretide and -1.09 (SD 2.443, n = 101) with placebo.
What remains uncertain
- The mouse study and the trial differ in species, in the cause of the muscle problem (aging versus a genetic mitochondrial disease), in how the drug was given and for how long, and in the outcomes measured, so the contrast illustrates the gap between a plausible mechanism and a human result and cannot show either study wrong.
- One negative trial in one population does not show the compound does nothing elsewhere. Elamipretide has an approved use in a different disease; see the check on SS-31 and elamipretide naming and the elamipretide profile.
- The registry values are observed group means by visit, not the trial's primary model, and WPF did not reconcile them with the paper's model-based estimates. WPF read the abstract, not the full text, so the paper's own fatigue estimate was not used here.
- Whether the trial's result reflects the drug, the population or the way outcomes were measured is not something this check can say.
What would change the answer
- A systematic comparison of how often positive animal results for peptides are reproduced in randomized human trials, which would replace this single example with a measured rate.
- An original animal study in a primary mitochondrial myopathy model with matching human endpoints, which would give a like-for-like contrast and could change what the example shows.
Exact gaps
- No original animal study in a primary mitochondrial myopathy model was found in the searches listed below. This does not show that none exists.
- The full text of the MMPOWER-3 paper was not read, and the paper's tables were not located.
Where WPF looked for missing evidence
Searched on 2026-11-14 in: Europe PMC (MEDLINE records); ClinicalTrials.gov API v2; PubMed E-utilities.
- Europe PMC: TITLE_ABS "SS-31" AND "mitochondrial myopathy" -> 0 records
- Europe PMC: TITLE_ABS elamipretide AND myopathy -> first 8 records reviewed: human trials, reviews and Barth syndrome reports, no animal disease-model study
- Europe PMC: TITLE_ABS (SS-31 OR elamipretide) AND (Ndufs4 OR Polg OR mitochondrial DNA OR respiratory chain deficiency OR Leigh) -> first 15 records reviewed, none a primary mitochondrial myopathy animal model
- Europe PMC: TITLE_ABS (SS-31 OR elamipretide) AND muscle AND (mice OR mouse) AND mitochondrial -> first 15 records reviewed; aged-mouse muscle studies were the closest (PMID 23692570 chosen)
Found: An aged-mouse skeletal muscle study (closest in tissue and in measured performance) and the MMPOWER-3 randomized trial. No primary mitochondrial myopathy animal model original was found.
Not searched: Embase; Full texts; Preprints; Records beyond the first page of each Europe PMC query.
Not finding evidence in these searches is not proof that none exists.
Date checked and review status
Checked: · version 1.6.0
Review status: AI-assisted source verification. Human review: none recorded. Human review is pending and has not happened.
Related pages
Profiles: /directory/elamipretide
Research journeys: /research/journey/elamipretide
What changed?: /research/changes#trial_result_posted
Cite this check
The citation names the version and an address that keeps returning what was checked, even after a newer version is published.
Cell and animal results versus human results: A good result in cells or animals shows a compound is worth testing in people. It does not show the compound works in people. For elamipretide (SS-31), aged mice showed better muscle energy use and endurance, but in a randomized phase 3 trial in adults with primary mitochondrial myopathy it did not beat placebo on walking distance or fatigue. The mouse work was in aging, not in this disease, so this illustrates the gap and does not show the mouse result was wrong. Verdict: Overstated. Cited from World Peptide Foundation, Peptide Claims & Evidence, version 1.6.0, claim cell-animal-result-works-in-people, checked 2026-11-14. AI-assisted source verification; human review none recorded.
Page:
https://www.worldpeptidefoundation.org/research/check/cell-animal-result-works-in-people
Versioned record:
https://www.worldpeptidefoundation.org/api/research/claims/cell-animal-result-works-in-people?version=1.6.0
Versioned record: /api/research/claims/cell-animal-result-works-in-people?version=1.6.0